Given their history of not meeting deadlines TDA, I can't imagine anyone taking any DCF valuation seriously (unfortunately). The US trials were actually meant to have started in the first quarter of this calendar year and we still haven't the foggiest of explanations from the company why they didnt proceed. Anyway hopefully our mysterious South American investor will do some cross-border "drug running" for us while we wait. and wait. and wait.....
bell potter target $1.20, page-17
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)